Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel molecular assays for monitoring T cell function after HSCT in two siblings with variants in <i>DCLRE1C</i>.

Journal of human immunity·2026
Same author

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

EBioMedicine·2026
Same author

Evaluation of Tetraspanins in Extracellular Vesicle Bioengineering.

Small science·2026
Same author

Dynamics of an RNase H-Responsive Tetrahedral DNA Nanostructure for Efficient Intracellular microRNA Inhibition.

Bioconjugate chemistry·2026
Same author

Viral Immunity in Immunoglobulin Products: Global Immunity Debt and Autoimmunity in the Postpandemic Era.

European journal of immunology·2026
Same author

T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

British journal of haematology·2025
Same journal

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review 2020-present.

Expert opinion on therapeutic patents·2026
Same journal

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).

Expert opinion on therapeutic patents·2026
Same journal

Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present).

Expert opinion on therapeutic patents·2026
Same journal

A patent review of GPR84 receptor antagonists (2020-present).

Expert opinion on therapeutic patents·2026
Same journal

SLIT2 and ROBO-Axis inhibitors for the treatment of cancer: a patent review (2020-2026).

Expert opinion on therapeutic patents·2026
Same journal

New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present).

Expert opinion on therapeutic patents·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Identification of Circular RNAs using RNA Sequencing
08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

Circular RNA interference effector molecules (WO10084371).

Per Lundin1, Pedro M D Moreno, C I Edvard Smith

  • 1Life Science Group, Albihns.Zacco Stockholm, Valhallavägen 117, SE-114 85 Stockholm, Sweden. per.lundin@albihnszacco.com

Expert Opinion on Therapeutic Patents
|November 30, 2010
PubMed
Summary
This summary is machine-generated.

Circularized interfering RNAs (ciRNAs) offer increased stability against degradation, showing promise for RNA interference (RNAi) therapeutics. However, conventional nucleotide modifications may suffice, with delivery challenges remaining the primary obstacle for clinical success.

More Related Videos

RNAi Interference by dsRNA Injection into Drosophila Embryos
08:30

RNAi Interference by dsRNA Injection into Drosophila Embryos

Published on: April 11, 2011

Related Experiment Videos

Last Updated: Jun 6, 2026

Identification of Circular RNAs using RNA Sequencing
08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

RNAi Interference by dsRNA Injection into Drosophila Embryos
08:30

RNAi Interference by dsRNA Injection into Drosophila Embryos

Published on: April 11, 2011

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Development

Background:

  • RNA interference (RNAi) therapeutics face challenges due to rapid degradation by nucleases.
  • Physicochemical and pharmacokinetic drawbacks hinder the clinical translation of RNAi-inducing agents.

Purpose of the Study:

  • To evaluate the therapeutic potential of circularized interfering RNAs (ciRNAs) generated via auto-catalytic intron splicing.
  • To assess ciRNAs against established nucleotide modification strategies for small interfering RNAs (siRNAs).

Main Methods:

  • Patent evaluation of WO10084371 focusing on ciRNA generation and properties.
  • Comparative analysis of ciRNA potency and stability against short hairpin RNAs (shRNAs).

Main Results:

  • ciRNAs demonstrate comparable potency to exogenously introduced shRNAs with enhanced exonuclease resistance.
  • Experimental evidence for the precise silencing mechanism of ciRNAs is limited, though Dicer-substrate potential is noted.

Conclusions:

  • While ciRNAs present an innovative approach to RNAi stability, current nucleotide modifications may offer adequate therapeutic stability.
  • Efficient delivery of RNAi agents remains the principal challenge for clinical applications, irrespective of the RNAi technology employed.